We are currently updating our website, and will have our new version online soon. Please check back later this fall.

Mailing List

Subscribe to the KT Canada mailing list

Login

Welcome

Signup

Once you have signed up, you will receive a confirmation email with your username and password. To activate your account, follow the instructions in the email.

 

Centre for Evidence-
Based Medicine

Example NNTs - Gastrointestinal

Condition or Disorder Intervention vs. Control Outcome Follow-up Duration Event Rates % NNT (95% CI)
CER EER
Endoscopic re-treatment of bleeding peptic ulcer1 Endoscopy vs. surgery Mortality at 30 days, duration of hospitalization after treatment, ICU stay, need for blood transfusion and treatment-related complications 6 weeks 36 15 5 (3 to 25)
Remission rates in active Crohn disease2 Budesonide vs. mesalamine Remission 16 weeks 36 62 4 (3 to 10)
Endoscopic gastroduodenal ulcers in osteoarthritis3 Rofecoxib vs. Ibuprofen Endoscopic gastroduodenal ulcers ≥ 3 mm at 12 weeks 24 weeks 7 25 5 (4 to 9)
Women with irritable bowel syndrome4 Alosetron vs. placebo Relief of abdominal symptoms 1 month 29 41 8 (5 to 22)
Constipation 3 30 4 (3 to 5)
Bleeding peptic ulcer5 Omeprazole vs. placebo Recurrent bleeding 8 weeks 22.5 6.7 6 (4 to 14)
Hospital stay < 5 days 31.7 46.7 7 (4 to 38)
H pylori infection6 Clarithromycin. Iansoprazole, metronidazole vs clarithromycin, Iasoprazole, amoxicillin Eradication of H pylori 6 weeks 84 66 6 (3 to infinity)

References

  1. Gastroenterology. Oct 1999; 117: 776-83
  2. N Engl J Med. 6 Aug 1998; 339: 370-4
  3. N Engl J Med. 6 Aug 1998; 339: 370-4
  4. Lancet. Mar 25, 2000; 355:1035-40
  5. N Engl J Med. Aug 3, 2000; 343: 310-6
  6. JAMA. 2003;290:1593-9